Compare TG Therapeutics Inc (TGTX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs GeneDx Holdings Corp — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: TG Therapeutics Inc is far larger — about 4.6× GeneDx Holdings Corp's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| TGTX | WGS | |
|---|---|---|
Market Cap | $8.26B | $1.80B |
Sector | Health | Technology |
52-Week High | $59.06 | $167.51 |
52-Week Low | $26.39 | $34.51 |
Enterprise Value | $8.50B | $1.80B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
